Wellstat sells uridine triacetate rights to BTG
Wellstat’s uridine triacetate is indicated as a treatment for accidental exposure to the chemotherapeutic 5-fluorouracil (5-FU). The agreement allows BTG to mark, sell and distribute uridine triacetate in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.